---

$2.65

-0.1750 ( -6.21% ) 394.7K

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2024-06-17	Buy	2835.00	Donhauser Peter D.O.
2024-05-17	Buy	5000.00	Thomas Steffen
2024-04-01	Sale	-73380.00	MISSLING CHRISTOPHER U
2024-02-23	Sale	-50000.00	Donhauser Peter D.O.
2024-02-23	Sale	-50000.00	Velden Claus Vander
2024-02-23	Sale	-50000.00	Thomas Steffen
2024-02-23	Sale	-50000.00	Ma Jiong
2024-02-23	Sale	-50000.00	Skarpelos Athanasios
2024-01-12	Sale	-125000.00	MISSLING CHRISTOPHER U
2024-01-12	Sale	-10000.00	Boenisch Sandra